Gilead Sciences, Inc.

October 13, 2020 A class action alleges Gilead Sciences and Bristol-Myers Squibb have for years conspired to restrain the U.S. market for HIV treatment drugs, allowing the companies to overcharge direct buyers.

May 22, 2020 Gilead Sciences unlawfully disclosed confidential medical information by sending envelopes labeled "HIV Prevention Team," a class action claims.

September 15, 2017 A lawsuit has been filed against Kite Pharma, Inc., its board of directors, Gilead Sciences, Inc., and Dodge Merger Sub, Inc. alleging the defendants issued a misleading registration statement regarding a proposed merger between Kite and Gilead.